Skip to content

Nation-wide bacteriological surveillance for Streptococcus pneumoniae in Pediatric invasive pneumococcal disease

Nation-wide bacteriological surveillance for Streptococcus pneumoniae in Pediatric invasive pneumococcal disease - Nation-wide bacteriological surveillance for Streptococcus pneumoniae in Pediatric invasive pneumococcal disease

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000006985
Enrollment
800
Registered
2012-01-04
Start date
2020-03-02
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Invasive pneumococcal disease, Pneumonia, Acute otitis media

Interventions

None listed

Sponsors

Takao Fujisawa
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: S.pneumoniae strains isolated from the following disease. 1)Invasive Pneumococcal Disease(IPD) Requirement; 1:Diagnosed as Bacterial meningitis, Bacteremia, Pneumonia, Arthritis, Peritonitis 2:S. pneumoniae is isolated from physiologically sterile site [spinal fluid, blood, tissue fluid]. 3:Age: over 2 months and under 16 years old 2)Pneumonia Requirement; 1:Diagnosed as Pneumonia by chest X-ray, the following symptoms are observed: pyrexia, cough, dyspnea, chest pain, general malaise and/or sputum 2:Age: over 2 months and under 5 years old. 3:S.pneumoniae is isolated from sputum according to the reference article method. 3)Acute otitis media [AOM] Requirement; 1:Diagnosed as AOM by the clinical symptoms and tympanic membrane findings. 2:Age: over 2 months and under 5 years old. 3:S.pneumoniae is isolated from specimen which is collected by Myringotomy or paracentesis of the tympanic membrane. 4:For avoiding contamination by Myringotomy, the specimen is collected by seed-swab.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

MeasureTime frame
1) Capsular serotype of clinically isolated S.pneumoniae 2) Minimum inhibitory concentration (MIC) of these isolates 3) MLST(Multilocus sequence typing)

Countries

Japan

Contacts

Public ContactMiwa Izutsu

CTD inc. Pneumocatch research office

info@pneumocatch.jp81-3-6228-4835

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026